DK1043399T3 - Hepatitis C Virus cellekultursystem - Google Patents

Hepatitis C Virus cellekultursystem

Info

Publication number
DK1043399T3
DK1043399T3 DK00105929T DK00105929T DK1043399T3 DK 1043399 T3 DK1043399 T3 DK 1043399T3 DK 00105929 T DK00105929 T DK 00105929T DK 00105929 T DK00105929 T DK 00105929T DK 1043399 T3 DK1043399 T3 DK 1043399T3
Authority
DK
Denmark
Prior art keywords
hcv
hepatitis
cell culture
culture system
virus cell
Prior art date
Application number
DK00105929T
Other languages
English (en)
Other versions
DK1043399T5 (da
Inventor
Ralf Dr Bartenschlager
Original Assignee
Ralf Dr Bartenschlager
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ralf Dr Bartenschlager filed Critical Ralf Dr Bartenschlager
Publication of DK1043399T3 publication Critical patent/DK1043399T3/da
Application granted granted Critical
Publication of DK1043399T5 publication Critical patent/DK1043399T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK00105929T 1999-04-03 2000-03-23 Hepatitis C virus cellekultursystem DK1043399T5 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19915178A DE19915178A1 (de) 1999-04-03 1999-04-03 Hepatitis C Virus Zellkultursystem

Publications (2)

Publication Number Publication Date
DK1043399T3 true DK1043399T3 (da) 2003-07-28
DK1043399T5 DK1043399T5 (da) 2004-01-05

Family

ID=7903452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00105929T DK1043399T5 (da) 1999-04-03 2000-03-23 Hepatitis C virus cellekultursystem

Country Status (12)

Country Link
US (1) US6630343B1 (da)
EP (1) EP1043399B9 (da)
JP (1) JP4903929B2 (da)
AT (1) ATE236988T1 (da)
AU (1) AU770486B2 (da)
CA (1) CA2303526C (da)
DE (2) DE19915178A1 (da)
DK (1) DK1043399T5 (da)
ES (1) ES2197031T4 (da)
HK (1) HK1034094A1 (da)
PT (1) PT1043399E (da)
SE (1) SE1043399T5 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
US6921634B2 (en) * 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
WO2002038793A2 (en) * 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
US20040005549A1 (en) * 2000-11-07 2004-01-08 Anadys Pharmaceuticals, Inc. Hepatitis C virus constructs characterized by high efficiency replication
JP2004516039A (ja) * 2000-12-22 2004-06-03 ベーリンガー インゲルハイム （カナダ） リミテッド Ｃ型肝炎ウイルスからの自己複製ｒｎａ分子
JP4299540B2 (ja) * 2001-01-23 2009-07-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｃ型肝炎ウイルスレプリコンおよびレプリコン増強細胞
WO2002072803A2 (en) * 2001-03-09 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Subgenomic replicons of the flavivirus dengue
CN1093172C (zh) * 2001-03-19 2002-10-23 杨凌岱鹰生物工程股份有限公司 丙型肝炎全病毒及其体外细胞培养方法
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
WO2003025209A1 (en) * 2001-09-21 2003-03-27 Ortho-Clinical Diagnostics, Inc. Use of hcv core antigen assay for screening of anti-viral compounds
US6689559B2 (en) 2001-11-29 2004-02-10 The Research Foundation Of The State University Of New York Efficient hepatitis C virus replicon and its use in identifying antiviral compounds
JP2005528885A (ja) * 2002-01-15 2005-09-29 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Ｇｂウイルスｂレプリコン及びレプリコン強化細胞
WO2003085084A2 (en) * 2002-04-03 2003-10-16 Smithkline Beecham Corporation Hepatitis c virus sub-genomic replicons
AU2003260578A1 (en) * 2002-04-04 2003-10-20 Achillion Pharmaceuticals, Inc. Hcv antiviral and cytotoxicity drug screening assay
WO2003089672A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
AU2003225479A1 (en) * 2002-04-26 2003-11-10 Pfizer Inc. Reporter-selectable hepatitis c virus replicon
DE50211264D1 (de) * 2002-09-16 2008-01-03 Pan Biotech Gmbh Einrichtung zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
WO2004033615A1 (de) 2002-09-16 2004-04-22 Pan-Biotech Gmbh Verfahren zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
US7455969B2 (en) * 2002-11-13 2008-11-25 Washington University Highly permissive cell lines for hepatitis C virus RNA replication
CA2514918C (en) * 2003-02-13 2012-07-03 Merck & Co., Inc. Method to confer cell culture replication activity to different hepatitis c virus isolates
US20040214178A1 (en) * 2003-04-24 2004-10-28 Agouron Pharmaceuticals, Inc. Reporter-selectable Hepatitis C virus replicon
WO2004104198A1 (ja) * 2003-05-26 2004-12-02 Toray Industries, Inc. 遺伝子型2aのC型肝炎ウイルス（HCV）ゲノム由来の核酸を含む核酸構築物、及び該核酸構築物を導入した細胞
WO2005009418A2 (en) 2003-07-25 2005-02-03 Idenix (Cayman) Limited Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
WO2005017125A2 (en) * 2003-08-14 2005-02-24 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-c virus
EP1666598B1 (en) * 2003-09-19 2015-08-12 Tokyo Metropolitan Institute of Medical Science Nucleic acid and gene originating in novel hcv strain and replicon-replicating cell using the gene
US7790448B2 (en) * 2003-09-19 2010-09-07 Tokyo Metropolitan Organization For Medical Research Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene
EP1685238A4 (en) 2003-11-05 2008-08-20 Merck & Co Inc REPLICONS OF HCV CONTAINING THE NS5B ISSUED GENOTYPE 2B
US8026092B2 (en) * 2003-12-01 2011-09-27 Board Of Regents, The University Of Texas System Replication competent hepatitis C virus and methods of use
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
US7659103B2 (en) * 2004-02-20 2010-02-09 Tokyo Metropolitan Organization For Medical Research Nucleic acid construct containing fulllength genome of human hepatitis C virus, recombinant fulllength virus genome-replicating cells having the nucleic acid construct transferred thereinto and method of producing hepatitis C virus Particle
JP5213228B2 (ja) 2004-03-02 2013-06-19 ビルコ・ビーブイビーエイ 臨床的カット−オフ値の推測
ATE465276T1 (de) * 2004-03-24 2010-05-15 Achillion Pharmaceuticals Inc Quantitativer test zum nachweis neu synthetisierter rna in einem zellfreien system sowie identifizierung von inhibitoren der rna- synthese
US20070166702A1 (en) * 2004-07-16 2007-07-19 Geert Leroux-Roels Methods for predicting the efficacy or outcome of hcv therapy
GB0419189D0 (en) * 2004-08-27 2004-09-29 Angeletti P Ist Richerche Bio New uses
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
CA2604442A1 (en) * 2005-04-11 2006-10-19 Mingjun Huang Pharmaceutical compositions for and methods of inhibiting hcv replication
US7465537B2 (en) * 2005-05-01 2008-12-16 The Board Of Trustees Of The University Of Arkansas Compounds and methods for inhibiting hepatitis C virus replication
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
CN101321865B (zh) 2005-09-30 2011-12-14 日本国立感染症研究所 感染性丙型肝炎病毒颗粒高效生产体系
EP1801116A1 (en) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV replicon shuttle vectors
BRPI0708393A2 (pt) * 2006-03-09 2011-05-31 Transgene Sa proteìna de fusão não estrutural do vìrus da hepatite c
FR2901807B1 (fr) * 2006-05-30 2013-08-23 Univ Victor Segalen Bordeaux 2 Nouveau traitement d'une infection par le vhc
WO2008148671A1 (en) * 2007-06-06 2008-12-11 F. Hoffmann-La Roche Ag Hcv ns3 replicon shuttle vectors
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
JP5753090B2 (ja) * 2008-10-29 2015-07-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良型ｈｃｖワクチンおよびその使用方法
WO2010074249A1 (ja) 2008-12-26 2010-07-01 東レ株式会社 Ｃ型肝炎ウイルス由来の核酸並びにそれを用いた発現ベクター、形質転換細胞及びｃ型肝炎ウイルス粒子
JP5780969B2 (ja) 2008-12-31 2015-09-16 サイネクシス，インコーポレーテッド シクロスポリンａの誘導体
US20100173281A1 (en) * 2009-01-06 2010-07-08 Roche Palo Alto Llc HCV NS3 protease replicon shuttle vectors
EP2417133A1 (en) 2009-04-06 2012-02-15 PTC Therapeutics, Inc. Compounds and methods for antiviral treatment
CA3080983C (en) 2009-05-27 2023-02-28 Pct Therapeutics, Inc. Method of inhibiting and reducing a viral infection
EP2471917A4 (en) 2009-08-28 2013-03-13 Tokyo Metropolitan Inst Medical Science POLYNUCLEOTIDE FROM A NEW HEPATITIS C VIRUS STRAIN AND USE THEREOF
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
JP2013516424A (ja) 2009-12-30 2013-05-13 サイネクシス，インコーポレーテッド シクロスポリン類似体
EP2686423A4 (en) 2011-03-14 2015-01-28 Nat Res Council Canada METHOD FOR PRODUCING VIRUSES IN CELLS
US9234184B2 (en) 2011-03-31 2016-01-12 Japan As Represented By Director-General Of National Institute Of Infectious Diseases Nucleic acid construct comprising nucleic acid derived from genome of hepatitis C virus of genotype 1B, hepatitis C virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis C virus particles
JP5927185B2 (ja) 2011-05-31 2016-06-01 国立感染症研究所長 Ｃ型肝炎ウイルスｊ６ｃｆ株ゲノム由来の変異体レプリコン
EP2752485A4 (en) 2011-08-31 2015-06-24 Japan As Represented By The Director General Of Nat Inst Of Infectious Diseases NUCLEIC ACID RECOMBINANT PRODUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOTYPE 3A GENE VHC GENOME
CA2886336A1 (en) 2012-09-28 2014-04-03 National University Corporation Kobe University Hepatitis c virus particles formation promoter, and method for producing hepatitis c virus particles
CN104099357B (zh) * 2013-04-12 2016-09-21 中国科学院上海生命科学研究院 检测蛋白质稳定性的方法及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1554662A (en) 1976-05-05 1979-10-24 Inverni Della Beffa Spa Polyhydroxyphenylchromanones
CH683594A5 (de) 1991-01-24 1994-04-15 Flachsmann Ag Emil Verfahren zur Herstellung eines Pflanzenextrakt enthaltenden Masse, welche insbesondere für die Einkapselung in ein festes Umhüllungsmaterial geeignet ist.
DE19501266A1 (de) 1995-01-18 1996-07-25 Madaus Ag Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen mit verbesserter Freisetzung und Resorbierbarkeit danach erhältliche Zubereitungen und deren Verwendung zur Herstellung von Arzneimitteln
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5851758A (en) * 1995-10-25 1998-12-22 Childrens Research Institute Cytopathic replication of hepatitis C virus in a new cell line
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US6524853B1 (en) * 1998-06-24 2003-02-25 Chugai Seiyaku Kabushiki Kaisha Vector expressing the full-length gene of RNA virus and use thereof

Also Published As

Publication number Publication date
JP2001017187A (ja) 2001-01-23
ATE236988T1 (de) 2003-04-15
US6630343B1 (en) 2003-10-07
ES2197031T3 (es) 2004-01-01
PT1043399E (pt) 2003-08-29
SE1043399T5 (sv) 2003-12-02
EP1043399A3 (de) 2002-05-08
JP4903929B2 (ja) 2012-03-28
ES2197031T4 (es) 2004-05-16
AU2518000A (en) 2000-10-19
AU770486B2 (en) 2004-02-26
CA2303526C (en) 2005-11-01
SE1043399T3 (sv) 2003-07-29
DE19915178A1 (de) 2000-10-05
DE50001673D1 (de) 2003-05-15
HK1034094A1 (en) 2001-10-12
EP1043399A2 (de) 2000-10-11
CA2303526A1 (en) 2000-10-03
DK1043399T5 (da) 2004-01-05
EP1043399B9 (de) 2003-10-08
EP1043399B1 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
ATE236988T1 (de) Hepatitis c virus zellkultursystem
Reiser et al. Serum interleukin 4 and interleukin 10 levels in patients with chronic hepatitis C virus infection
Pavio et al. The hepatitis C virus persistence: how to evade the immune system?
Lanford et al. The chimpanzee model of hepatitis C virus infections
HK1092498A1 (en) Composition containing the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
IT1278077B1 (it) Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
DE69334357D1 (de) Nachweis und Typisierung das Hepatitis C Virus (HCV) mittels 5'UTR und NS5 Nukleinsäuresequenzen
FI924349A0 (fi) Antigenkombinationer av hepatit c virus (hcv) foer anvaendning i immunobestaemningar av anti-hcv motkroppar.
GR3006171T3 (da)
NZ518999A (en) Vaccine compositions
MX9708679A (es) Sustratos disociables, solubles de la proteasa del virus de la hepatitis c.
EP0460056A4 (en) Non-a, non-b hepatitis hepatocyte cell culture
ATE430167T1 (de) Humaner rekombinanter antikörper gegen das hepatitis c (hcv) nichtstrukturelles ns3 protein, nukleinsäure und deren verwendungen
KR980002263A (ko) C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
DE60038023D1 (de) Neue gbv sequenz
Yuki et al. Changes in Antibodies to Specific Hepatitis C Virus Antigens with Interferon-α Therapy: Analysis by Recombinant Immunoblot Assay.
Niu et al. Hepatitis C virus type I (1a) in Northern China
Cavinta Antibodies to hepatitis C virus major antigens associated with certain stages of hepatitis C virus infection.
EP1424390A4 (en) INTAKE HEPATITIS-C VIRUS AND METHOD FOR ITS CULTURE IN AN IN VITRO CELL CULTURE